Reviewed Mar 2026 | PubMed sources
Active Market
This comparison can feed directly into US-first legal, provider, and cost workflows.

CJC-1295 vs Sermorelin: Head-to-Head Comparison

Both are GHRH analogs but CJC-1295 was engineered for a dramatically longer half-life. Sermorelin has a 10-20 minute half-life requiring daily injections, while CJC-1295 with DAC lasts days. Sermorelin has the advantage of former FDA approval and a longer safety track record.

Approved Comparison Routing

Approved options in this comparison

A
Sermorelin

Sermorelin is currently modeled on this site as an approved treatment path for: Diagnosis and treatment of growth hormone deficiency in children. Brand names in the current dataset: Geref.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Want to discuss Sermorelin with a provider?

Sermorelin is currently modeled on this site as an approved treatment path. Use the provider matcher to narrow fit by state, insurance, budget, and urgency.

Find a provider

Side-by-Side Comparison

DimensionCJC-1295Sermorelin
Evidence LevelPhase II trials, published PK dataFormerly FDA-approved; decades of clinical use
FDA StatusNot approvedPreviously FDA-approved
MechanismModified GHRH(1-29) with Drug Affinity ComplexGHRH(1-29) analog, natural sequence
Half-Life~6-8 days (with DAC)~10-20 minutes
Dosing Frequency1-2x per week (DAC version)Daily injections required
Side EffectsInjection site reactions, water retentionFacial flushing, headache, injection pain
GH Release PatternSustained elevation (less physiological)Pulsatile, mimics natural rhythm
Evidence Level
CJC-1295
Phase II trials, published PK data
Sermorelin
Formerly FDA-approved; decades of clinical use
FDA Status
CJC-1295
Not approved
Sermorelin
Previously FDA-approved
Mechanism
CJC-1295
Modified GHRH(1-29) with Drug Affinity Complex
Sermorelin
GHRH(1-29) analog, natural sequence
Half-Life
CJC-1295
~6-8 days (with DAC)
Sermorelin
~10-20 minutes
Dosing Frequency
CJC-1295
1-2x per week (DAC version)
Sermorelin
Daily injections required
Side Effects
CJC-1295
Injection site reactions, water retention
Sermorelin
Facial flushing, headache, injection pain
GH Release Pattern
CJC-1295
Sustained elevation (less physiological)
Sermorelin
Pulsatile, mimics natural rhythm

Peptide Overviews

CJC-1295

BHuman Studies

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Available in two forms: with and without Drug Affinity Complex (DAC), which extends its half-life.

Growth Hormone SecretagoguesNot Approved
View full CJC-1295 profile →

Sermorelin

AFDA Approved

Sermorelin is the shortest fully functional fragment of GHRH (amino acids 1-29). It was the first GHRH analog approved by the FDA, marketed as Geref for diagnostic and therapeutic use. Geref was subsequently discontinued in the U.S. market, though sermorelin remains available through compounding pharmacies. Geref was subsequently discontinued in the U.S. market, though sermorelin remains available through compounding pharmacies.

Growth Hormone SecretagoguesFDA Approved
View full Sermorelin profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

CJC-1295 vs Sermorelin: FAQ